CytomX Therapeutics
CTMX

$1.50

2.82%

Market Cap: 117M

About: CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Employees: 122

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

3,430% more call options, than puts

Call options by funds: $353K | Put options by funds: $10K

238% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 8

91% more capital invested

Capital invested by funds: $50.6M [Q4 2023] → $96.6M (+$46M) [Q1 2024]

28% more funds holding

Funds holding: 68 [Q4 2023] → 87 (+19) [Q1 2024]

16.69% more ownership

Funds ownership: 48.73% [Q4 2023] → 65.42% (+16.69%) [Q1 2024]

21% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 24

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$3

100%

upside

Avg. target

$4.66

210%

upside

High target

$8

433%

upside

7 analyst ratings

3 positive

43%

4 neutral

57%

0 negative

0%

Piper Sandler Joseph Catanzaro	133%upside $3.5	Overweight Upgraded	28 May 2024
BMO Capital Etzer Darout	139%upside $3.59	Market Perform Maintained	9 May 2024
Wedbush Robert Driscoll	433%upside $8	Outperform Upgraded	9 May 2024
Jefferies Roger Song	433%upside $8	Buy Upgraded	6 May 2024
BMO Capital Etzer Darout	117%upside $3.25	Market Perform Reiterated	1 May 2024

See Analyst Rankings

Financial journalist opinion

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

Buy Alert: 3 Penny Stocks That Will Explode in 2024

When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience.

Buy Alert: 3 Penny Stocks That Will Explode in 2024

No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.

Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.80 and back.

No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.

CytomX Therapeutics Announces New Employment Inducement Grants

Why Is CytomX (CTMX) Stock Down 43% Today?

CytomX Therapeutics (NASDAQ: CTMX ) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics latest clinical trail update covers its Phase 1a study of CX-904.

Why Is CytomX (CTMX) Stock Down 43% Today?

CytomX stock down 30% despite encouraging cancer study results

CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing.

CytomX stock down 30% despite encouraging cancer study results

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

See News Rankings